Mfc

MFC Co., Ltd. focuses on developing and manufacturing active pharmaceutical ingredients (APIs), key starting materials (KSM), and pharmaceutical intermediates (PI).

Using its proprietary high-purity crystallization technology, the company was the first in the world to commercialize TBFA, a key starting material for statin-class cholesterol drugs, which it now supplies exclusively in the domestic market.

It has built market competitiveness by supplying APIs to major domestic pharmaceutical companies including JW Pharmaceutical, Huons, and Samjin Pharmaceutical.

As new growth drivers, the company is expanding a pipeline of improved-generic APIs including tegoprazan, ilaprazole, rosuvastatin, gemigliptin, upadacitinib, memantine, and felbinac.

Beyond API supply, it is broadening into contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) businesses, and has achieved a supply milestone by successfully synthesizing high-purity antibody-drug conjugate (ADC) linkers in collaboration with a subsidiary of a global pharmaceutical company.

In new business areas, it operates the MFC AI Formulation Research Center specialized in AI-based drug formulation research, and is carrying out a government-funded project worth roughly KRW 20 billion over four years and nine months to develop an AI-based platform for predicting impurities and related substances in medicines.

Through open collaboration with institutions such as Korea University College of Medicine and Kookmin University, it is also pursuing joint research on new drugs including sarcopenia treatments.

While the company's sales have historically been weighted toward the domestic market, it is pursuing a strategy of API registration and export expansion into Indonesia, Taiwan, Japan, and Vietnam, and it listed on KOSDAQ in December 2024.

Consolidated revenue in 2025 was KRW 20.80 billion, a slight increase from KRW 20.60 billion in 2024, but operating profit fell sharply to KRW 297 million from KRW 1.46 billion in 2024, pulling the operating margin down from 7.1% to 1.4%.

Net income attributable to owners, however, turned positive at KRW 822 million in 2025, in contrast to net losses of KRW -1.18 billion in 2024 and KRW -721 million in 2023. The quarterly trajectory has been uneven.

Q2 2025 was strong, with revenue of KRW 5.41 billion, operating profit of KRW 643 million, and net income of KRW 1.13 billion, but Q3 operating profit dropped to just KRW 0.7 million and net income fell back into a loss of KRW -188 million.

In Q4, revenue was KRW 5.01 billion with an operating loss of KRW 454 million and a net loss of KRW 156 million, and in Q1 2026 revenue slipped to KRW 3.18 billion as the operating loss widened to KRW 347 million and the net loss to KRW 565 million.

Q2 2026 swung back to profit, with revenue of KRW 5.998 billion, operating profit of KRW 239 million, and net income of KRW 300 million.

The company explained that a government drug-pricing reform announced in November of the prior year triggered industry-wide inventory adjustments that reduced customer orders, and that demand gradually recovered after the reform was finalized in March of this year.

Reflecting this volatility, cumulative net income attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) remains negative at KRW -609 million.

On the balance sheet, the debt ratio has steadily declined from 53.7% in 2023 to 28.5% in 2024 and 18.7% in 2025, while operating cash flow improved from KRW 9.26 million in 2023 to KRW 2.65 billion in 2024 and KRW 2.39 billion in 2025.

Korea's API industry is showing moderate growth on the back of rising chronic-disease treatment demand from an aging population and continued investment by global pharmaceutical companies in API production capacity.

The domestic gastroesophageal reflux disease treatment market is estimated at around KRW 400 billion, while statin-class cholesterol drug prescriptions are estimated at roughly KRW 2 trillion.

The company has explained that a government drug-pricing reform created temporary industry-wide uncertainty, leading to reduced orders from domestic pharmaceutical companies between Q4 2025 and Q1 2026.

Overseas, Indonesia's API market is projected to grow from USD 1.3 billion in 2023 to USD 2.1 billion by 2030, and the fact that Indonesia imports roughly 80% of its APIs is seen as a favorable environment for domestic API companies.

The improved-generic drug market is viewed as an area where profitability can be secured through shorter development timelines and pricing advantages relative to original drugs, as improved generics can maintain 70% of listed price for three years upon launch and extend this for up to eight years, compared with a cap of 54% for standard generics.

Hana Securities assessed that developing APIs through new crystalline forms can circumvent original patents, generating higher added value than standard generics.

In terms of competitive positioning, the company points to its status as the world's first commercializer of TBFA, a key statin starting material it supplies exclusively, as a key technology differentiator.

The company has described 2026 as the inaugural year of an earnings 'quantum leap' driven by improved-generic API launches and CMO/CDMO expansion.

It has stated that launches of improved-generic APIs for cholesterol treatment, including rosuvastatin and ilaprazole, are planned for the second half, and that API volumes ordered by a large pharmaceutical company are scheduled to begin shipping from the fourth quarter.

The company has set a target of achieving a 50/50 split between domestic and overseas sales within five years, with a 30% share goal in Japan and a 20% share goal across global markets including the United States, Europe, and Southeast Asia as key priorities.

In the CDMO area, it has built a production and supply collaboration framework after successfully synthesizing high-purity ADC linkers and passing qualification testing in partnership with a subsidiary of a global pharmaceutical company.

Through its AI formulation research center, it is pursuing development of a related-substance and impurity prediction platform along with advanced formulation technology, aiming eventually to license this technology out to global pharmaceutical companies.

With Korea University College of Medicine, it has agreed to extend joint research on muscle-disease treatments, including sarcopenia therapies for astronauts, into space-environment applications.

Hana Securities stated in a June 2026 report that certain improved-generic pipeline candidates could launch in the fourth quarter of 2026 if clinical results are successful.